Lessons

    1. How did you establish your IR clinic?

      FREE PREVIEW

    2. How was TACE developed and how has it evolved over time?

    3. What are the three integral components of conventional TACE?

    4. How do you properly mix the drug solution and Lipiodol for administration?

    5. How do different types and sizes of embolic particles impact embolization procedures and outcomes?

    6. How are common side effects like taste changes and pain managed in TACE procedures?

    7. How do the procedural protocols for patients with neuroendocrine tumors differ?

    8. What are the key clinical trials that have had the most impact on modern IO practice?

    9. What is the current role of chemoembolization compared to Y-90 in the treatment of HCC?

    10. CME/CE Reflection: Module I

    1. Can you give a backround on systemic therapy for HCC?

      FREE PREVIEW

    2. Can you go into the basic science of how immunotherapy works?

    3. How do HCC referrals come into your practice?

    4. Tell us about how your tumor board works?

    5. Tell us about the trials that have put us where we are in the BCLC algorithm?

    6. Tell me why you would choose one local regional therapy over an other?

    7. Why would you choose one local regional therapy over another and what would you choose?

    8. Is combination therapy for HCC safe for patients?

    9. Do you favor Conventional TACE or DEB TACE, and how do you do it?

    10. How do you treat multifocal HCC?

    11. When do you re-image patients after treatment?

    12. CME/CE Reflection: Module II

    1. Describe your practice and the importance of the teamwork required to maintain a busy tertiary referral center

      FREE PREVIEW

    2. Can you describe the evolution of treatment for HCC at Ochsner?

    3. Tell us about your referral patterns for these patients

    4. Take us through the patient preparation process for treatment of HCC

    5. What are some strategies for improving throughput and prioritizing patients via multidisciplinary care

    6. Tell us about patient selection and your treatment algorithm for HCC

    7. What is your approach to lobar treatment, and when do you target specific areas for treatment?

    8. Tell us about how Y-90 works and the concept of the sphere conundrum

    9. Can you talk about how the sphere conundrum directs your approach?

    10. How do you consider the margins around the tumor when treating with Y-90?

    11. Do you have helpful dosimetry software and when did you start using it?

    12. Talk about how you-re selecting your dose

    13. What do you do when you have a centrally located big tumor with multiple feeders?

    14. With underlying liver disease, do you have a cutoff for how much volume you want to preserve?

    15. Are you publishing any of your findings?

    16. Can you talk about combination therapies with systemic?

    17. CME/CE Reflection: Module III

About this course

  • 39 lessons
  • 2 hours of content
  • Earn up to 3 CME/CE credits